- Home
- VRCA vs PEPG Comparison
VRCA vs PEPG Comparison
Compare VRCA & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- PEPG
- Stock Information
- Founded
- VRCA 2013
- PEPG 2018
- Country
- VRCA United States
- PEPG United States
- Employees
- VRCA N/A
- PEPG N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- PEPG Health Care
- Exchange
- VRCA Nasdaq
- PEPG Nasdaq
- Market Cap
- VRCA 54.0M
- PEPG 52.4M
- IPO Year
- VRCA 2018
- PEPG 2022
- Fundamental
- Price
- VRCA $0.58
- PEPG $1.40
- Analyst Decision
- VRCA Hold
- PEPG Buy
- Analyst Count
- VRCA 5
- PEPG 3
- Target Price
- VRCA $6.00
- PEPG $7.67
- AVG Volume (30 Days)
- VRCA 254.0K
- PEPG 169.8K
- Earning Date
- VRCA 08-13-2025
- PEPG 08-07-2025
- Dividend Yield
- VRCA N/A
- PEPG N/A
- EPS Growth
- VRCA N/A
- PEPG N/A
- EPS
- VRCA N/A
- PEPG N/A
- Revenue
- VRCA $7,179,000.00
- PEPG N/A
- Revenue This Year
- VRCA $171.87
- PEPG N/A
- Revenue Next Year
- VRCA $71.38
- PEPG N/A
- P/E Ratio
- VRCA N/A
- PEPG N/A
- Revenue Growth
- VRCA N/A
- PEPG N/A
- 52 Week Low
- VRCA $0.38
- PEPG $0.88
- 52 Week High
- VRCA $8.98
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- VRCA 49.82
- PEPG 48.28
- Support Level
- VRCA $0.60
- PEPG $1.37
- Resistance Level
- VRCA $0.71
- PEPG $1.49
- Average True Range (ATR)
- VRCA 0.07
- PEPG 0.09
- MACD
- VRCA -0.00
- PEPG -0.00
- Stochastic Oscillator
- VRCA 43.69
- PEPG 38.46
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.